Runx3基因启动子甲基化检测对乳腺癌患者早期诊断的临床意义

摘要

目的 探讨血浆Runx3基因启动子甲基化检测对诊断早期乳腺癌的临床意义.方法 2009年10月～2010年10月收集经病理确诊的乳腺癌患者60例,采用DNA甲基化特异性PCR方法检测60例乳腺癌患者的癌组织、癌旁正常组织及血浆中Runx3基因启动子异常甲基化情况.GraphPad Prism 4统计软件对乳腺癌组织和血浆中Runx3基因甲基化行x2检验分析.结果 癌旁正常组织中Runx3异常甲基化为6.67％,癌组织中Runx3异常甲基化率为58.33％,血浆中为78.33％,血浆中甲基化改变与癌组织甲基化改变具有显著相关性.Runx3基因甲基化与乳腺癌患者的年龄、肿瘤大小无相关性(x2分别为0.951,0.287,P＞0.05),而与患者临床分期和淋巴结转移密切相关(x2=5.188,P=0.023),其中癌组织中Ⅰ期+Ⅱ期患者甲基化率与Ⅲ期+Ⅳ期患者甲基化率比较差异显著(x2=8.625,P=0.003).结论 血浆Runx3基因启动子甲基化检测对早期诊断乳腺癌有一定诊断参考价值.%Objective To investigate the plasma Runx3 gene promoter methylation detection in diagnosis of early breast cancel and its clinical significance. Methods 60 cases with breast cancer confirmed by pathology were collected from October 2009 to October 2010,using DNA methylation specific PCR detection of 60 cases of breast carcinoma,adjacent normal tissue and plasma in Runx3 gene aberrant promoter methylation status. GraphPad Prism 4 statistical software was used in breast cancel tissue and plasma Runx3 gene methylation in line χ2 test analysis. Results The adjacent normal tissue in aberrant methylation of Runx3 was 6. 67%, carcinoma of aberrant Runx3 methylation rate was 58. 33% and 78. 33% respectively in the plasma, plasma methylation and cancer methylation changes significantly correlated with methylation of Runx3 gene and breast cancer patient age. Tumor size was not correlated with patients' age (χ2=0. 951,0. 287, P>0. 05) ,but closely correlated with clinical stage and lymph node (χ2=5. 188, P=0. 023). Among them,the cancer stage Ⅰ and stage Ⅱ patients methylation rate and Ⅲ +Ⅳ patients methylation rates compared with remarkable difference(χ2 =8. 625, P=0. 003). Conclusion The plasma Runx3 gene promoter methylation detection in early diagnosis of breast cancer have a certain reference to diagnostic value.